Symptoms of peripheral arterial disease: ramipril

199 m maximum walking (2013a) p=0.001 distance at 24 weeksb Selected secondary outcomes: Change in mean Ahimastos Not Not Difference pain-free walking et al. reported reported 227 seconds time at 24 weeks (2006) 95% CI 175 seconds to 278 seconds p<0.001 Change in mean Shahin et Not Not Difference 122 m pain-free walking al. reported reported 95% CI 56 m to 188 m distance at (2013a) p=0.001 24 weeksb Change in median Ahimastos Not 16% Comparison with WIQ distance score et al. reported p<0.001c placebo not reported at 24 weeks (2006) Change in median Ahimastos Not 15% Comparison with WIQ speed score at et al. reported p<0.001c placebo not reported 24 weeks (2006) Change in median Ahimastos Not 50% Comparison with WIQ stair climbing et al. reported p<0.001c placebo not reported score at 24 weeks (2006) Quality of life at Shahin et No significant 24 weeksb al. differences between (2013a) the groups in SF-36, EQ-5D or VascuQoL scores Safety Ahimastos n=20 n=20 et al. (2006) Shahin et n=17 n=12 al. (2013a) Patients reporting Ahimastos None None adverse events et al. (2006) Shahin et 2/19 (10.5%) 4/14 (28.6%) No statistical analyses al. withdrew reported reported (2013a) giving no cough reason 1/14
